Big Tech meets Big VC meets Big Pharma: the new power plays reshaping HealthTech

General Catalyst partnered with AWS to provide distribution for its 100+ HealthTech portfolio companies through Amazon's cloud infrastructure. This is not a typical cloud deal: it is a systematic pipeline connecting VC-backed startups with enterprise healthcare buyers via AWS's sales channels.

Andreessen Horowitz is launching a TechBio fund with Eli Lilly, signaling that top-tier VCs now collaborate with Big Pharma rather than trying to disrupt them. The fund combines a16z's technology expertise with Lilly's clinical development infrastructure and regulatory know-how.

These partnerships mark a maturation of the HealthTech market: the capital-intensive, highly regulated nature of healthcare means that collaboration between VCs, Big Tech, and pharma is more effective than competition.

Over 10 years after spending $4 billion+ on Epic, Kaiser Permanente is working with Innovaccer to build a neutral data layer on top of its Epic system. This enables value-based care contracts, population health management, and AI deployment in ways that Epic's native architecture was not designed to support.

The strategic significance is clear: even the most sophisticated health system in the US does not view its EHR as sufficient for the AI era. KP needs a layer above Epic that can integrate data from multiple sources, run AI models, and support new care delivery models. This is the post-EHR architecture that other health systems will eventually adopt.

Dedalus, the Italian hospital EHR/EMR provider, is a top-2 player in most European markets. But its closed system architecture hinders interoperability and limits the ability to layer AI and modern workflow tools on top.

A new buyer with HealthTech companies in its portfolio (like an Innovaccer equivalent) could 'open' Dedalus and drive hospital digital transformation in Europe. The Dedalus sale could become the most consequential European hospital IT deal of the decade if the right buyer sees it as a platform play rather than a legacy software acquisition.

Even traditional players like IQVIA are launching AI agents, signaling that the category has reached peak hype. The question for 2025 is whether AI agents in healthcare will deliver measurable value or become the next wave of vaporware.

History suggests the truth will be somewhere in between: narrow, well-scoped agents (documentation, scheduling, patient follow-up) will prove their value, while ambitious autonomous agents (end-to-end prior authorization, clinical triage) will fall short of their promises. The M&A cycle will begin by late 2025 as the market separates viable products from overvalued demos.